Overview

Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma

Status:
Unknown status
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the the efficacy and safety of Anlotinib in combination with STUPP regimen for patients with newly diagnosed glioblastoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Temozolomide